Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 7/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzophenone SCHEMBL1043759 | 0.81 | KMT2A (0.59) | ALDH1A1PLOD2CYP3A4HPGDHIF1A | |
| Benzoic Acid SCHEMBL28126463 | 0.81 | NAPRT (0.54) | ALDH1A1PLOD2CYP3A4HPGDHIF1A | |
| Hydrochlorthiazide SCHEMBL4937016 | 0.80 | GSK3B (0.68) | GSK3BALDH1A1MEN1KMT2AMAPK1 | |
| Pyridine SCHEMBL18321129 | 0.79 | GSK3B (0.76) | GSK3BPTPN1ALDH1A1PLOD2CYP3A4 | |
| SCHEMBL18849535 | 0.78 | GSK3B (1.00) | GSK3BPTPN1ALDH1A1CYP3A4HPGD | |
| SCHEMBL19331717 | 0.78 | GSK3B (1.00) | GSK3BPTPN1ALDH1A1CYP3A4HPGD | |
| SCHEMBL7621 | 0.78 | GSK3B (1.00) | GSK3BPTPN1ALDH1A1CYP3A4HPGD | |
| Benzamide SCHEMBL6784039 | 0.78 | CYP3A4 (0.57) | ALDH1A1PLOD2CYP3A4HPGDHIF1A | |
| Hydrogen Sulfide SCHEMBL7496567 | 0.76 | GSK3B (0.95) | GSK3BPTPN1ALDH1A1CYP3A4HPGD | |
| Methane SCHEMBL7161301 | 0.76 | GSK3B (0.95) | GSK3BPTPN1ALDH1A1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101823861-B | PTB (Phenacyl Thiazolium Bromide) waterproof ventilated type aerated concrete block interface agent and use method thereof | CHINA FUJIAN COMPAKTUNA SUNSHINE BUILDING MATERIALS CO LTD | 2012-08-01 | — | — | CN | disclosed |
| CN-101823861-A | PTB (Phenacyl Thiazolium Bromide) waterproof ventilated type aerated concrete block surfactant and use method thereof | CHINA FUJIAN COMPAKTUNA SUNSHINE BUILDING MATERIALS CO LTD | 2010-09-08 | — | — | CN | disclosed |
| US-20080293931-A1 | Methods and compositions for the removal of nucleic acid amplification inhibitors | LOS ALAMOS NATIONAL SECURITY, LLC | 2008-11-27 | — | — | US | disclosed |
| US-20070065841-A1 | Methods and compositions for the removal of nucleic acid amplification inhibitors | ENERGY, U.S. DEPARTMENT OF | 2007-03-22 | — | — | US | disclosed |
| EP-1243581-B1 | Pyridinium compounds useful for the treatment of AGE-related diseases | TORRENT PHARMACEUTICALS LTD (IN) | 2005-07-13 | — | — | EP | disclosed |
| EP-1373263-B1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | TORRENT PHARMACEUTICALS LTD (IN) | 2004-10-27 | — | — | EP | disclosed |
| WO-2002085897-A9 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2004-04-01 | — | — | WO | disclosed |
| EP-1222171-B1 | PYRIDINIUM DERIVATIVES FOR THE MANAGEMENT OF AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | TORRENT PHARMACEUTICALS LTD (IN) | 2004-02-25 | — | — | EP | disclosed |
| EP-1373263-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | Torrent Pharmaceuticals Ltd (IN) | 2004-01-02 | — | — | EP | disclosed |
| US-20030092744-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-05-15 | — | — | US | disclosed |
| WO-2002085897-A1 | HETEROCYCLIC COMPOUNDS FOR AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS | SANKARANARAYANAN ALANGUDI (IN) | 2002-10-31 | — | — | WO | disclosed |
| US-6462057-B1 | SUCH AS 1-(2-ETHOXY-2-OXOETHYL)-3-(METHANESULFONYLHYDRAZINO-CARBONYL)PYRIDINIUM BROMIDE; KIDNEY DISEASE, NERVE DAMAGE, ATHEROSCLEROSIS, RETINOPATHY, DERMATOLOGICAL DISORDERS AND DISCOLORATION OF TEETH | TORRENT PHARMACEUTICALS, LTD. (IN) | 2002-10-08 | — | — | US | disclosed |
| EP-1243581-A1 | Pyridinium compounds useful for the treatment of AGE-related diseases | Torrent Pharmaceuticals Ltd (IN) | 2002-09-25 | — | — | EP | disclosed |
| EP-1222171-A1 | PYRIDINIUM DERIVATIVES FOR THE MANAGEMENT OF AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Torrent Pharmaceuticals Ltd (IN) | 2002-07-17 | — | — | EP | disclosed |
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2001-08-30 | — | — | US | disclosed |
| WO-2001025208-A1 | PYRIDINIUM DERIVATIVES FOR THE MANAGEMENT OF AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANKARANARAYANAN ALANGUDI (IN) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | AGER, GLA, RBP1 | GSK3B 2250/4885PTPN1 3060/4885ALDH1A1 769/4885 |
| US-20030092744-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | AGER, REN, RBP4 | GSK3B 1728/4885PTPN1 2172/4885ALDH1A1 634/4885 |
| US-20080293931-A1 | Methods and compositions for the removal of nucleic acid amplification inhibitors | POLRMT, FBL, POLL | GSK3B 3452/4885PTPN1 3866/4885ALDH1A1 2004/4885 |
| US-20070065841-A1 | Methods and compositions for the removal of nucleic acid amplification inhibitors | POLRMT, FBL, POLL | GSK3B 3452/4885PTPN1 3866/4885ALDH1A1 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.